海利生物(603718.SH):控股股東更名為“上海豪園創業投資發展有限公司”
格隆匯12月2日丨海利生物(603718.SH)公佈,公司於2019年12月2日收到控股股東通知,其名稱已由“上海豪園科技發展有限公司”變更為“上海豪園創業投資發展有限公司”,註冊資本金由1500萬元人民幣增至3000萬元人民幣,營業期限由2019年12月21日延長至2029年12月21日,經營範圍由“從事計算機科技領域內的技術開發、技術諮詢、技術服務、技術轉讓,自有房屋租賃,計算機、軟件及輔助設備、辦公用品、電子產品的批發、零售。”變更為“創業投資業務,創業投資諮詢業務,代理其他創業投資企業等機構或個人的創業投資業務,為創業企業提供創業管理服務業務,參與設立創業投資企業與創業投資管理顧問機構。”上述變更事項相關工商登記手續已辦理完畢。除上述變更外,控股股東其他基本信息均無變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.